



# ELMMB Formulary Updates

## December 2019

## Subscribe Now

And be one of the first to know...

### BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- **Prasterone** – Not recommended for use in ELHE
- **Liothyronine** - updated RMOG guidance acknowledged – remain BLACK Traffic Light
- **Suliqua®** – insulin glargine/lixisenatide – not accepted for use in ELHE
- **Ospemifene** [Sensio®] – vulvar & vaginal atrophy in post-menopausal women
- **Bezlotoxumab** - preventing clostridium difficile infection – [NICE TA601](#) appraisal terminated
- **Aliskiren** – in line with NHSE Low priority prescribing commissioning Guidance
- **Brentuximab vedotin** – untreated advanced Hodgkin lymphoma – appraisal terminated
- **Idelalisib** – refractory follicular lymphoma – not recommended by [NICE TA604](#)
- **Ketotifen unit dose eye drops** [Ketofall®] – not approved for use by ELMMB
- **Lenalidomide with bortezomib & dexamethasone** – untreated multiple myeloma – [NICE TA603](#) appraisal terminated
- **Minocycline** - in line with NHSE Low priority prescribing commissioning guidance
- **Fortacin** [Lidocaine/Prilocaine Spray] – Primary premature ejaculation in adult men
- **Ibrutinib** – with rituximab – Waldenstrom's macroglobulinaemia – [NICE TA608](#) appraisal terminated
- **Ramucirumab** – unresctable hepatocellular carcinoma after sorafenib – [NICE TA609](#) appraisal terminated
- **Pomalidomide with bortezomib & dexamethasone** – relapsed or refractory multiple myeloma – [NICE TA602](#) appraisal terminated
- **Dymista®** - not recommended for use in ELHE

### RED traffic light - Primary care prescribers should not be asked to prescribe (\*\* denotes NHS England Commissioned)

- **Atezolizumab\*\*** – metastatic non-squamous non-small-cell lung cancer – [NICE TA584](#)
- **Lenalidomide\*\*** – myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality – [NICE TA322](#) updated
- **Risankizumab** – moderate to severe plaque psoriasis – [NICE TA596](#) – [Fast Track]
- **Cemiplimab** – metastatic or locally advanced cutaneous squamous cell carcinoma – [NICE TA592](#) [Cancer Drugs Fund]
- **Artesunate injection** – severe malaria caused by Plasmodium Falciparum [microbiology recommendation only]
- **Ceftolozane/tazobactam** – multi drug resistant infections, [microbiology use only]
- **Sodium zirconium cyclosilicate** – hyperkalaemia – [NICE TA599](#)
- **Ocrelizumab\*\*** – primary progressive multiple sclerosis – [NICE TA585](#)
- **Lanalidomide\*\*** – multiple myeloma in people who have received at least 2 prior therapies – [NICE TA171](#) updated
- **Blinatumomab\*\*** – acute lymphoblastic leukaemia in remission with minimal residual disease activity – [NICE TA589](#)
- **Ribociclib with fulvestrant** – hormone receptor-positive, HER2 negative, advanced breast cancer – [NICE TA593](#) [Cancer Drugs Fund]
- **Human Chorionic Gonadotrophin (Gonasi®)** – hypogonadotropic hypogonadism, endocrinologists use only
- **Xeomin®** (Botulinum neurotoxin type A) – chronic sialorrhoea – [NICE TA605](#)
- **Pembrolizumab\*\* with carboplatin & paclitaxel** – untreated metastatic squamous non-small-cell lung cancer – [NICE TA600](#)
- **Lenalidomide + dexamethasone\*\*** – multiple myeloma after 1 treatment with bortezomib - [NICE TA586](#)
- **Lenalidomide + dexamethasone\*\*** – previously untreated multiple myeloma – [NICE TA587](#)
- **Nusinersen\*\*** – spinal muscular atrophy – [NICE TA588](#)
- **Enoxaparin** – Acute Coronary Syndrome, 2<sup>nd</sup> line option when fondaparinux is contraindicated
- **Dacomitinib\*\*** – untreated EGFR mutation-positive non-small-cell lung cancer – [NICE TA595](#)
- **Olaparib** – maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to 1<sup>st</sup> line platinum-based chemotherapy – [NICE TA598](#) [Cancer Drugs Fund]
- **Lanadelumab** – recurrent attacks of hereditary angioedema – [NICE TA606](#)
- **Benralizumab** – severe eosinophilic asthma – [NICE TA565](#) (updated)





# ELMMB Formulary Updates

December 2019... continued

Subscribe Now

And be one of the first to know...

## AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **BioXtra® Saliva Replacement Gel** – for patients who have had radiotherapy to oral cavity
- **Navina®** – trans anal irrigation product [[continence service only](#)]
- **Rivaroxaban** – (Xarelto®) prevention of atherothrombotic events in people with coronary or peripheral artery disease – [NICE TA607](#)
- **Ciclosporin eye drops** [Verkazia®] severe vernal keratoconjunctivitis
- **Brivaracetam** – use in children – accepted for ELHE
- **Propranolol oral** – infantile haemangiomas, off license use
- **Febuxostat** – Traffic Light switched to amber following [Drug Safety Alert](#)
- **Aminophylline tablets** – treatment/prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis.
- **Systane Balance®** - evaporative dry eye, specialist initiation only
- **Dapagliflozin with insulin** – Type 1 diabetes – [NICE TA597](#)
- **Testogel** – (Testavan®) – Male hypogonadism [[shared care](#)]
- **Nutrizym 22 capsules** – 2<sup>nd</sup> line option when intolerant to Creon®
- **Trihexphenidyl liquid** – dystonic symptoms in children with neurodevelopment conditions

## GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- **Rosuvastatin** – second line option in patients with a higher CV risk.
- **Ertugliflozin with metformin & a dipeptidyl peptidase-4 inhibitor** – type 2 diabetes - an option [in NICE TA583](#)
- **Tranexamic acid injection for topical use** – switched to GREEN

## Guidelines

- [Clopidogrel Patient Information Leaflet](#) – updated version
- [Adult Male Testosterone Guidance for Primary Care](#) – accepted for use
- [Lancashire Care Subcutaneous Syringe Pump Protocol](#) – updated
- [ADHD Shared Care Guideline](#) – updated
- [Medicines for Minor Health Conditions, Dry Eye](#) – PILs acknowledged for use by ELMMB
- [Insulin Toujeo Information Sheet](#) - updated
- [Chronic Non-Cancer Pain Guidelines](#) updated
- [Continence and Catheter Care Formulary](#) – updated
- [Lithium Shared Care Guideline](#) – updated
- [Leg Cramps \[quinine\] Patient Information Leaflet](#)
- [Trans Male & Trans Female Hormone Therapy in Gender Dysphoria Prescribing Information Sheet](#)
- [Monitoring Requirements of High Risk Drugs in Primary Care](#) – updated
- [SPS – DOAC dosing in renal impairment](#)
- [NMP Policy](#) – updated
- [Psoriasis: Biologic & High Cost Drugs Commissioning Pathway](#)
- [Bisphosphonates for osteoporosis resources](#) – acknowledged by ELMMB
- [Latest Wound Care Formulary \(ELHT\)](#)

## Other

- [Medicines Management Board Minutes](#)
- [MHRA Drug Safety Updates](#)
- [Drug Safety Updates](#)
- [Prescribing Hot Topics](#)
- [Flu Information](#)
- [Nice Bites](#)
- [NICE Visual Summaries](#)
- [ELMMB updates](#)